Antwan Tolhoek tests positive for anabolic androgenic steroids

Antwan Tolhoek raced for Trek-Segafredo/Lidl-Trek in the past two seasons
Antwan Tolhoek raced for Trek-Segafredo/Lidl-Trek in the past two seasons (Image credit: Getty Images)

The UCI has announced the provisional suspension of Dutch climber Antwan Tolhoek following a positive test for anabolic androgenic steroids in an out-of-competition test last November.

29-year-old Tolhoek, who in the last two years raced for Lidl-Trek before moving to Continental level with Portuguese team Sabgal-Anicolor for 2024, tested positive in a sample collected on November 27 last year.

Thank you for reading 5 articles in the past 30 days*

Join now for unlimited access

Enjoy your first month for just £1 / $1 / €1

*Read any 5 articles for free in each 30-day period, this automatically resets

After your trial you will be billed £4.99 $7.99 €5.99 per month, cancel anytime. Or sign up for one year for just £49 $79 €59

Join now for unlimited access

Try your first month for just £1 / $1 / €1

Dani Ostanek
Senior News Writer

Dani Ostanek is Senior News Writer at Cyclingnews, having joined in 2017 as a freelance contributor and later being hired full-time. Prior to joining the team, they had written for numerous major publications in the cycling world, including CyclingWeekly and Rouleur.

 

Dani has reported from the world's top races, including the Tour de France, World Championships, and the spring Classics. They have interviewed many of the sport's biggest stars, including Mathieu van der Poel, Remco Evenepoel, Demi Vollering, and Anna van der Breggen.

 

As well as original reporting, news and feature writing, and production work, Dani also oversees How to Watch guides and works on The Leadout newsletter throughout the season. Their favourite races are Strade Bianche and Paris-Roubaix and their favourite published article is from the 2024 edition of the latter: 'Unless I'm in an ambulance, I'm finishing this race' – Cyrus Monk, the last man home at Paris-Roubaix